Sugi Predict
/ Targets
/ MAP3K13
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MAP3K13 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma |
PHASE4 | UNKNOWN |
| Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome |
PHASE3 | COMPLETED |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer |
PHASE2 | COMPLETED |
| A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma |
PHASE1/PHASE2 | COMPLETED |
| Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer |
PHASE2 | COMPLETED |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations |
PHASE2 | RECRUITING |
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma |
PHASE1/PHASE2 | COMPLETED |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations |
PHASE2 | ACTIVE_NOT_RECRUITING |
| HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant |
PHASE2 | RECRUITING |
| Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer |
PHASE2 | COMPLETED |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. |
PHASE2 | UNKNOWN |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma |
PHASE1/PHASE2 | SUSPENDED |
| Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer |
PHASE2 | COMPLETED |
| MEK162 for Patients With RAS/RAF/MEK Activated Tumors |
PHASE2 | COMPLETED |
| Dabrafenib + Trametinib + PDR001 In Colorectal Cancer |
PHASE2 | UNKNOWN |
| A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 |
PHASE1 | COMPLETED |
| Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer |
PHASE1 | COMPLETED |
| Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 |
PHASE1 | WITHDRAWN |
| BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) |
PHASE1 | COMPLETED |
| Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo |
nan | UNKNOWN |
| Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies |
nan | RECRUITING |
| Clinical Genetics Branch Eligibility Screening Survey |
nan | NOT_YET_RECRUITING |
| BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients |
nan | COMPLETED |
| Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment |
nan | ACTIVE_NOT_RECRUITING |
| Molecular Analysis of Thoracic Malignancies |
nan | ENROLLING_BY_INVITATION |
| Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial |
nan | RECRUITING |
| RASopathy Biorepository |
nan | RECRUITING |
| p-AKT Expression on Clinical Outcomes in Malignant Lymphoma |
nan | COMPLETED |
| Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a MAP3K13 binder may also engage these)